治疗高血症的新策略
Stefano Masi1, Herman Dalpiaz2, Sara Piludu2
1Department of Clinical and Experimental Medicine, University of Pisa, Italy.
European journal of internal medicine
|November 3, 2024
概括
在接受氨酸- ангиотензин- 阿尔多素系统抑制剂 (RAASi) 和矿物质皮质体受体对抗剂 (MRAs) 的患者中,管理高卡莱米亚至关重要. 本综述探讨了管理高血症的新策略,使心血管疾病患者能够继续接受RAASi和MRA治疗.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
背景情况:
- 列宁- ангиотензин- алдостерон系统抑制剂 (RAASi) 和矿物质皮质糖类受体对抗剂 (MRA) 对于控制心血管疾病 (CVD) 至关重要,包括高血压,糖尿病,慢性病和心力衰竭 (HF).
- 超血是使用RAASi和MRAs的患者的一个显著不良事件,通常导致剂量减少或停止治疗,从而危及患者的治疗结果.
- 超血症的低最佳管理可以增加脆弱患者群体的死亡率和发病率风险.
研究的目的:
- 审查新兴的治疗方案,以管理心血管疾病患者的高卡莱米亚.
- 总结最近的国际指南建议,以确保RAASi和MRA治疗的安全延续.
- 为临床医生提供以证据为基础的战略,以优化心血管和病患者的高卡莱米亚管理.
主要方法:
- 最近临床试验和指导方针的文献综述.
- 综合了关于新型高血管理剂的数据.
- 对RAASi和MRA治疗在高胆固醇血症背景下当前推的分析.
主要成果:
- 几种新的结合剂为治疗高血症提供了有希望的替代品.
- 最近的指导方针强调主动的高血症管理,以允许持续使用RAASi和MRAs.
- 有效的高血症控制可以防止治疗中断,改善心血管和的结果.
结论:
- 超血病管理的新策略对于在心血管疾病患者中保持RAASi和MRA治疗的好处至关重要.
- 遵守最新的指导方针可以促进这些关键药物的持续使用.
- 积极管理高卡血症是改善心血管和慢性病患者长期治疗结果的关键.
相关概念视频
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
463
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
463
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
914
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
914
01:26Heart Failure Drugs: Inotropic Agents
525
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
525
01:22Heart Failure Drugs: Diuretics
345
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
709
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
709
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391